Dyspareunia
Adult: For the treatment of moderate to severe cases caused by postmenopausal vulvar and vaginal atrophy: 6.5 mg (1 pessary) once daily at bedtime. Treatment should be reassessed at least every 6 months.
Chỉ định và Liều dùng
Vaginal
Dyspareunia Adult: For the treatment of moderate to severe cases caused by postmenopausal vulvar and vaginal atrophy: 6.5 mg (1 pessary) once daily at bedtime. Treatment should be reassessed at least every 6 months.
|
Chống chỉ định
Undiagnosed abnormal vaginal bleeding, untreated endometrial hyperplasia, history of known or suspected breast cancer, known or suspected estrogen-dependent malignant tumours (e.g. endometrial cancer), acute liver disease or history of liver disease wherein LFTs have failed to return to normal, previous or current venous thromboembolism (e.g. DVT, pulmonary embolism), known thrombophilic disorders (e.g. protein S, protein C, antithrombin deficiency), active or recent arterial thromboembolic disease (e.g. angina, MI), porphyria.
|
Thận trọng
Patient with hypertension, diabetes mellitus (with or without vascular involvement), SLE, migraine or severe headache, asthma, epilepsy, cholelithiasis, otosclerosis, leiomyoma or endometriosis; history of endometrial hyperplasia, women who have undergone hysterectomy due to endometriosis; risk factors for thromboembolic disorders (e.g. older age, major surgery, prolonged immobilisation, obesity [BMI >30 kg/m2], use of estrogens); risk factors for estrogen dependent tumours (e.g. 1st degree heredity for breast cancer); liver disorders (e.g. liver adenoma).
|
Tác dụng không mong muốn
Investigations: Weight fluctuations.
Reproductive system and breast disorders: Vaginal discharge, abnormal Pap smear. Rarely, benign breast mass, cervical/uterine polyps. |
Chỉ số theo dõi
Perform physical (including breast and pelvic) examination and obtain a complete personal and family medical history before initiating therapy. Monitor for excessive bleeding or vaginal discharge.
|
Tác dụng
Description:
Mechanism of Action: Prasterone is an inactive endogenous steroid that is converted into active androgens and/or estrogens. Its exact mechanism of action is not fully established, however, studies suggest that it exhibits androgenic and estrogenic activity. Synonym: dehydroepiandrosterone (DHEA). Pharmacokinetics: Metabolism: Metabolised by dehydrogenase, reductase, and aromatase into 2 active metabolites (estradiol and testosterone). |
Đặc tính
|
Bảo quản
Store between 5-30°C. Do not freeze. Follow applicable procedures for receiving, handling, administration, and disposal.
|
Phân loại MIMS
|
Phân loại ATC
A14AA07 - prasterone ; Belongs to the class of androstan derivative anabolic steroids used as systemic anabolic agents.
|
Tài liệu tham khảo
Anon. Prasterone. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 20/04/2022. Anon. Prasterone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/12/2021. Buckingham R (ed). Prasterone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/12/2021. Intrarosa (Millicent US, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 21/12/2021. Intrarosa 6.5 mg Pessary (Basic Pharma Manufacturing B.V.). European Medicines Agency [online]. Accessed 21/12/2021. Intrarosa Pessary 6.5 mg (Endoceutics Pharma [MSH] Inc). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 20/04/2022. Joint Formulary Committee. Prasterone. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/12/2021.
|